Stockscreener 앱 받기
21.82
1.93%
-0.43
시간 외 거래:
21.82
전일 마감가:
$22.25
열려 있는:
$22.15
하루 거래량:
327.48K
Relative Volume:
0.48
시가총액:
$1.01B
수익:
$681.75M
순이익/손실:
$70.47M
주가수익비율:
15.05
EPS:
1.45
순현금흐름:
$173.19M
1주 성능:
-2.11%
1개월 성능:
-11.37%
6개월 성능:
-11.01%
1년 성능:
+7.70%
1일 변동 폭
$21.26
$22.25
1주일 범위
$21.26
$22.95
52주 변동 폭
$11.16
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
명칭
Pacira Biosciences Inc
전화
650-242-8052
주소
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
PCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
21.82 | 1.03B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
152.82 | 68.32B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.66 | 46.55B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.85 | 43.80B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.33 | 19.01B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
306.41 | 13.79B | 2.99B | 1.21B | 1.13B | 25.06 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-30 | 업그레이드 | Truist | Sell → Hold |
| 2024-08-13 | 다운그레이드 | Truist | Buy → Sell |
| 2024-08-12 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2024-08-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-07 | 재개 | JP Morgan | Overweight |
| 2023-12-20 | 개시 | Raymond James | Outperform |
| 2023-08-03 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | 재개 | Wedbush | Outperform |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-01-03 | 재개 | JP Morgan | Overweight |
| 2021-07-26 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-04-21 | 재개 | JP Morgan | Neutral |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | 재확인 | Needham | Buy |
| 2020-05-27 | 개시 | Guggenheim | Neutral |
| 2020-04-07 | 개시 | Northland Capital | Outperform |
| 2020-03-20 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-24 | 개시 | SunTrust | Buy |
| 2020-01-23 | 개시 | SunTrust | Buy |
| 2019-11-06 | 개시 | BTIG Research | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-06 | 업그레이드 | Mizuho | Underperform → Neutral |
| 2019-05-02 | 업그레이드 | Stifel | Sell → Hold |
| 2019-02-01 | 다운그레이드 | Mizuho | Neutral → Underperform |
| 2018-08-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-21 | 재확인 | Mizuho | Neutral |
| 2018-02-16 | 다운그레이드 | Needham | Buy → Hold |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2018-01-04 | 재확인 | Canaccord Genuity | Buy |
| 2018-01-03 | 개시 | Leerink Partners | Mkt Perform |
모두보기
Pacira Biosciences Inc 주식(PCRX)의 최신 뉴스
Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025 - GlobeNewswire
Leading Non-Opioid Pain Therapy Maker Pacira Sets Q2 2025 Earnings DateKey Details Inside - Stock Titan
Pacira BioSciences, Inc. (NASDAQ:PCRX) Holdings Boosted by New York State Common Retirement Fund - Defense World
What drives Pacira BioSciences Inc. stock priceExceptional profit velocity - Autocar Professional
Is Pacira BioSciences Inc. a good long term investmentUnrivaled growth potential - jammulinksnews.com
Pacira BioSciences Inc. Stock Analysis and ForecastMarket-crushing stock picks - jammulinksnews.com
Pacira, JNJ in pact to boost Zilretta availability (PCRX) - Seeking Alpha
Pacira BioSciences Announces Strategic Collaboration to Signific - GuruFocus
Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts - The Manila Times
Major Expansion: J&J to Co-Promote Pacira's ZILRETTA Across 7M Annual Knee Injections Market - Stock Titan
Bank of New York Mellon Corp Decreases Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
What analysts say about Pacira BioSciences Inc. stockFree Stock Market Return Analysis - Autocar Professional
Zacks Research Has Negative Estimate for PCRX Q4 Earnings - Defense World
Teacher Retirement System of Texas Lowers Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Further Weakness as Pacira BioSciences (NASDAQ:PCRX) Drops 5.9% This Week, Taking Three-year Losses to 60% - 富途牛牛
Shareholders in Pacira BioSciences (NASDAQ:PCRX) have lost 60%, as stock drops 5.9% this past week - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Reach Out - ACCESS Newswire
Why Pacira BioSciences Inc. stock attracts strong analyst attentionFree Expert-Led Investment Training - Newser
Pacira BioSciences Investors: Know Your Rights Amid Lawsuit - AInvest
Investors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit - PR Newswire
Principal Financial Group Inc. Increases Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Target Price at $26.44 - Defense World
Pacira BioSciences announces workforce reduction and facility changes By Investing.com - Investing.com Nigeria
Finance Watch: Karyopharm Cuts Jobs In Cash Crunch; Pacira’s Layoffs Attributed To Efficiency - insights.citeline.com
What makes Pacira BioSciences Inc. stock price move sharplyFree Real-Time Stock Data - Newser
Pacira announces layoffs due to efficiencies in Exparel production - MSN
Pacira BioSciences Gene Therapy Shows Sustained Knee Osteoarthritis Improvement - MSN
Allspring Global Investments Holdings LLC Makes New $277,000 Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences (PCRX) Plunges 3.33% Amid Restructuring - AInvest
Pacira Pharmaceuticals Implements Workforce Reduction for Efficiency - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Connect - ACCESS Newswire
Pacira BioSciences announces workforce reduction and facility changes - Investing.com Australia
Pacira stock slips amid layoffs in U.S. (PCRX:NASDAQ) - Seeking Alpha
Pacira BioSciences announces workforce reduction - MarketScreener
GAMMA Investing LLC Increases Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Pacira Pharmaceuticals Secures New $300M Credit Facility - The Globe and Mail
Murano (MRNO) targets $500M for Bitcoin Treasury via new SEPA | PCRX SEC FilingForm 8-K - Stock Titan
Where are the Opportunities in (PCRX) - news.stocktradersdaily.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Pacira Biosciences Inc (PCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.25%
0.75%
자본화:
|
볼륨(24시간):